Use of Cell-Penetrating Peptides and/or Antibody Drug Conjugates for Tumor Radiosensitization
The current invention and method demonstrate the use of ADC to radiosensitize tumors, provide a decrease in toxicity and improvement in efficacy as measured in tumor models. The use of ADC with IR offers several advantages that can result in improved patient outcomes, specifically the reduction of risk in developing tumor resistance as well as other advantages.
The invention is purposed for use in personalized medicine for the radiosensitization of tumors utilizing drug conjugated activatable cell penetrating peptides (ACPP) or ADC as tumor selective delivery vehicles for potent radiosensitizers
Researchers at UC San Diego have demonstrated the therapeutic potential of utilizing cell penetrating peptides and antibody drug conjugates (ADC) to deliver radiosensitizers. Moreover, pretargeted ACPP technology allows for selective delivery of radiosensitizing agents to tumor as opposed to normal tissue and improvement in the therapeutic index of radiation therapy for non-resectable, locally aggressive tumors. Once cleaved, they release drug-conjugated polycation cell penetrating peptides that are taken up by tumor cells. Alternatively, ADC consist of a drug that is covalently attached to an antibody recognizing a specific cell surface receptor. The ADC binds to the specific receptor and undergoes receptor-mediated endocytosis whereby the drug is released from the antibody via endolysomal proteases.
20180140703
State Of Development Antibody drug conjugates (ADC) were synthesized and the conjugated antibodies were validated in vitro on tumor xenographs which radiosensitized tumor cells. Intellectual Property Info A provisional patent has been submitted and the technology is available for licensing. Related Materials Tech ID/UC Case 29124/2017-022-0 Related Cases 2017-022-0
USA
